$Apexigen (APGN.US)$ Apexigen will never reach the predicted...

Apexigen will never reach the predicted high of $9.00 before the approximate "Mid-2023" acquisition by Pyxis Oncology (a Pfizer back company). Apexxigen is already laying employee off and those who stay and are deemed essential enough to stay are already siging insentive contracts that will grant them an exercise purchase price of $2.65 per share with an expiration date as far in the future as 2032. In order for this deal to benefit Pyxis Oncology upfront the deal would have to be ratified before the stock reaches 0.64 per share. If it is ratified there after then Pyxis Oncology in conjuntion with Pfizer has a long term view that they have aready taken into account. Plan it to take 20% of my shares off the table when it reaches 0.64 per share and 100% of my original investment if it reaches $1.00 so I can then play with 100% house money.